STSS - NASDAQ
Sharps Technology, Inc.
$1.84
+1.1%Sharps Technology Inc., a medical device company, researches, designs, develops, manufactures, distributes, and sells safety syringe products in the United States. It offers Sharps Provensa, an ultra-low waste space syringe for the administration of various vaccines and injectable medications. The company was incorporated in 2017 and is based in Melville, New York.
At a Glance
Live SnapshotSharps Technology, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Negative gross margin indicates the company is losing money on each sale—unsustainable long-term.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Sharps Technology, Inc. Income Statement
STSS • NASDAQ
| Sharps Technology, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
REVENUE | |||||||
204.1K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||
(617.4K) | (773.9K) | (891.2K) | (654.6K) | (28.7K) | (11K) | (10.6K) | |
-413.3K | -773.9K | -891.2K | -654.6K | -28.7K | -11K | -10.6K | |
OPERATING INCOME | |||||||
(12.9M) | (7.1M) | (9.2M) | (8.1M) | (4.5M) | (2.3M) | (2M) | |
(19.5M) | (7.1M) | (8.5M) | (6.5M) | (2.8M) | (1.5M) | (1.7M) | |
(198.8K) | -58K | (729.5K) | (1.6M) | (1.7M) | (827K) | (388K) | |
-13.3M | -7.9M | -10.1M | -8.7M | -4.5M | -2.3M | -2.1M | |
PRE-TAX INCOME | |||||||
(416.7K) | (1.7M) | (0.0) | (1.3M) | (167.5K) | (0.0) | (0.0) | |
-416.7K | -1.7M | 138.1K | -1.3M | -166.7K | 3.3K | 0.0 | |
-6.8M | (0.0) | -15.2K | (0.0) | (0.0) | (0.0) | (0.0) | |
-257M | -1.5M | 255K | 4.1M | -166.7K | -6.9K | 3.6K | |
-270.3M | -9.3M | -9.9M | -4.6M | -4.7M | -2.3M | -2.1M | |
NET INCOME | |||||||
(0.0) | -30K | -30K | (0.0) | (0.0) | (0.0) | (3.0) | |
-282.5M | -9.3M | -9.8M | -4.6M | -4.7M | -2.3M | -2.1M |
SEC Filings
STSS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 29, 2026 | May 29, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 31, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 23, 2026 | February 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 16, 2026 | January 15, 2026 | 2026 | |
S-3/A S-3/A (Amended) N/A | December 23, 2025 | December 23, 2025 | ||
8-K 8-K 2025 N/A | December 23, 2025 | December 19, 2025 | 2025 | |
S-3/A S-3/A (Amended) N/A | December 23, 2025 | December 23, 2025 | ||
10-Q 10-Q 2025 Q3 Q3 | November 14, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your STSS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.